Payment overview · 2025
General Payments
$25.00
1 reported records · 1 companies
Healthcare provider profile · identity verified
Angelo Coppola, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · CAROLINA, PR · NPI 1083676456
Verified facts
What the public records show
CMS Open Payments records show Angelo Coppola, M.D. received $25.00 in general payments during 2025 across 1 reported records.
AstraZeneca Pharmaceuticals LP accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 141 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Symbicort by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $25.00 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $25.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $25.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
141 | 24 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
53 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 982 | 340 |
| Gabapentin | Gabapentin | 743 | 193 |
| Losartan Potassium | Losartan Potassium | 576 | 194 |
| Metformin Hcl | Metformin Hcl | 565 | 187 |
| Levothyroxine Sodium | Levothyroxine Sodium | 538 | 139 |
| Amlodipine Besylate | Amlodipine Besylate | 490 | 155 |
| Clonazepam | Clonazepam | 461 | 102 |
| Simvastatin | Simvastatin | 381 | 132 |
| Pantoprazole Sodium | Pantoprazole Sodium | 378 | 97 |
| Metoprolol Succinate | Metoprolol Succinate | 364 | 119 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 309 | 115 |
| Glimepiride | Glimepiride | 282 | 87 |
| Famotidine | Famotidine | 276 | 76 |
| Temazepam | Temazepam | 244 | 42 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 228 | 77 |
| Diclofenac Sodium | Diclofenac Sodium | 220 | 103 |
| Synthroid | Levothyroxine Sodium | 219 | 64 |
| Irbesartan | Irbesartan | 207 | 66 |
| Omeprazole | Omeprazole | 201 | 46 |
| Cilostazol | Cilostazol | 191 | 60 |
| Lisinopril | Lisinopril | 179 | 57 |
| Baclofen | Baclofen | 177 | 89 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 164 | 32 |
| Clopidogrel | Clopidogrel Bisulfate | 163 | 52 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 151 | 49 |
| Jardiance | Empagliflozin | 147 | 33 |
| Farxiga | Dapagliflozin Propanediol | 141 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 137 | 88 |
| Montelukast Sodium | Montelukast Sodium | 136 | 47 |
| Hydrochlorothiazide | Hydrochlorothiazide | 134 | 47 |
| Tamsulosin Hcl | Tamsulosin Hcl | 134 | 44 |
| Alprazolam | Alprazolam | 133 | 30 |
| Carvedilol | Carvedilol | 107 | 39 |
| Metformin Hcl Er | Metformin Hcl | 102 | 36 |
| Alendronate Sodium | Alendronate Sodium | 98 | 28 |
| Escitalopram Oxalate | Escitalopram Oxalate | 97 | 37 |
| Finasteride | Finasteride | 95 | 27 |
| Eliquis | Apixaban | 94 | 21 |
| Furosemide | Furosemide | 91 | 22 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 88 | 25 |
| Donepezil Hcl | Donepezil Hcl | 88 | 30 |
| Tradjenta | Linagliptin | 87 | 12 |
| Allopurinol | Allopurinol | 84 | 25 |
| Quetiapine Fumarate | Quetiapine Fumarate | 81 | 22 |
| Candesartan Cilexetil | Candesartan Cilexetil | 79 | 25 |
| Mometasone Furoate | Mometasone Furoate | 79 | 47 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 78 | 33 |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 78 | 14 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 73 | 42 |
| Sertraline Hcl | Sertraline Hcl | 72 | 25 |
| Trazodone Hcl | Trazodone Hcl | 72 | 25 |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 70 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 67 | 22 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 67 | 14 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 67 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 66 | 21 |
| Doxazosin Mesylate | Doxazosin Mesylate | 62 | 23 |
| Levo-T | Levothyroxine Sodium | 62 | 22 |
| Latanoprost | Latanoprost | 61 | 14 |
| Lansoprazole | Lansoprazole | 60 | 13 |
| Lorazepam | Lorazepam | 59 | 13 |
| Tramadol Hcl | Tramadol Hcl | 59 | 25 |
| Ezetimibe | Ezetimibe | 58 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 54 | 12 |
| Symbicort | Budesonide/Formoterol Fumarate | 53 | 15 |
| Xarelto | Rivaroxaban | 53 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 51 | 19 |
| Humulin N | Insulin Nph Human Isophane | 49 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 48 | 18 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 46 | 18 |
| Memantine Hcl | Memantine Hcl | 45 | 11 |
| Naproxen | Naproxen | 44 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 42 | 14 |
| Meclizine Hcl | Meclizine Hcl | 42 | 16 |
| Methylprednisolone | Methylprednisolone | 40 | 39 |
| Sildenafil Citrate | Sildenafil Citrate | 40 | 12 |
| Candesartan-Hydrochlorothiazid | Candesartan/Hydrochlorothiazid | 39 | 15 |
| Humalog Mix 75-25 | Insulin Lispro Protamin/Lispro | 39 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 39 | 12 |
| Mirtazapine | Mirtazapine | 39 | 11 |
| Pentoxifylline | Pentoxifylline | 39 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 38 | 29 |
| Entresto | Sacubitril/Valsartan | 38 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 38 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 37 | 27 |
| Verapamil Er | Verapamil Hcl | 37 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 36 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 36 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 35 | 12 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 34 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 34 | 14 |
| Spironolactone | Spironolactone | 32 | 13 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 31 | 11 |
| Bupropion Xl | Bupropion Hcl | 31 | 11 |
| Azithromycin | Azithromycin | 30 | 30 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 30 | 27 |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 30 | 12 |
| Nifedipine Er | Nifedipine | 30 | suppressed |
| Sucralfate | Sucralfate | 30 | suppressed |
| Mupirocin | Mupirocin | 29 | 17 |
| Buspirone Hcl | Buspirone Hcl | 28 | suppressed |
| Cefadroxil | Cefadroxil | 27 | 24 |
| Ramipril | Ramipril | 27 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 27 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 27 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 26 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 26 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 25 | suppressed |
| Pregabalin | Pregabalin | 25 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Prednisolone Sodium Phosphate | Prednisolone Sodium Phosphate | 24 | 23 |
| Insulin Syringe | Syring-Needl,disp,insul,0.3 Ml | 23 | suppressed |
| Lamotrigine | Lamotrigine | 23 | suppressed |
| Meloxicam | Meloxicam | 23 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 23 | suppressed |
| Glipizide Er | Glipizide | 22 | suppressed |
| Ibuprofen | Ibuprofen | 22 | 11 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 22 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 22 | suppressed |
| Ozempic | Semaglutide | 22 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 22 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 21 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 21 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 21 | suppressed |
| Prednisone | Prednisone | 21 | suppressed |
| Premarin | Estrogens, Conjugated | 21 | suppressed |
| Valsartan | Valsartan | 21 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 20 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | 14 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Levetiracetam | Levetiracetam | 20 | suppressed |
| Linzess | Linaclotide | 20 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 20 | suppressed |
| Combigan | Brimonidine Tartrate/Timolol | 19 | suppressed |
| Insulin Lispro | Insulin Lispro | 19 | suppressed |
| Levoxyl | Levothyroxine Sodium | 19 | suppressed |
| Nabumetone | Nabumetone | 19 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 19 | suppressed |
| Bumetanide | Bumetanide | 18 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 18 | suppressed |
| Anastrozole | Anastrozole | 17 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 17 | suppressed |
| Cefdinir | Cefdinir | 17 | 17 |
| Clotrimazole | Clotrimazole | 17 | 11 |
| Diclofenac Potassium | Diclofenac Potassium | 17 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 17 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 17 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 17 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Ketoconazole | Ketoconazole | 16 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 16 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Mounjaro | Tirzepatide | 15 | suppressed |
| Naproxen Sodium | Naproxen Sodium | 15 | suppressed |
| Sulindac | Sulindac | 15 | suppressed |
| Sure Comfort | Syring-Needl,disp,insul,0.3 Ml | 15 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 15 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 15 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Fluocinolone Acetonide Oil | Fluocinolone Acetonide Oil | 14 | 13 |
| Metronidazole | Metronidazole | 14 | 11 |
| Unifine Pentips | Pen Needle, Diabetic | 14 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Indapamide | Indapamide | 13 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 12 | suppressed |
| Eletriptan Hbr | Eletriptan Hydrobromide | 12 | suppressed |
| Humalog | Insulin Lispro | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | 12 |
| Topiramate | Topiramate | 12 | suppressed |
| Trueplus Insulin Syringe | Syring-Needl,disp,insul,0.3 Ml | 12 | suppressed |
| Trulicity | Dulaglutide | 12 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 11 | suppressed |
| Cabergoline | Cabergoline | 11 | suppressed |
| Carbidopa-Levodopa-Entacapone | Carbidopa/Levodopa/Entacapone | 11 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 11 | suppressed |
| Ciclopirox | Ciclopirox | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Humulin N Kwikpen | Insulin Nph Human Isophane | 11 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 11 | suppressed |
| Trelstar | Triptorelin Pamoate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $25.00 · 1 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error